This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Aceprometazine" – news · newspapers · books · scholar · JSTOR (February 2020) (Learn how and when to remove this template message)
Aceprometazine
Aceprometazine.svg
Clinical data
Pregnancy
category
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
MetabolismHepatic
ExcretionRenal and fecal
Identifiers
  • 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
ECHA InfoCard100.033.315 Edit this at Wikidata
Chemical and physical data
FormulaC19H22N2OS
Molar mass326.46 g·mol−1
3D model (JSmol)
  • O=C(c2cc1N(c3c(Sc1cc2)cccc3)CC(N(C)C)C)C
  • InChI=1S/C19H22N2OS/c1-13(20(3)4)12-21-16-7-5-6-8-18(16)23-19-10-9-15(14(2)22)11-17(19)21/h5-11,13H,12H2,1-4H3 checkY
  • Key:XLOQNFNTQIRSOX-UHFFFAOYSA-N checkY
  (verify)

Aceprometazine (INN) is a phenothiazine derivative prescription drug with neuroleptic and anti-histamine properties It is not widely prescribed, and may be associated with drug-induced Parkinsonism.[1] It may be used in combination with meprobamate for the treatment of sleep disorders. This combination is available in France under the trade name Mepronizine.

It is structurally related to the phenothiazine derivative veterinary drug acepromazine.

References

  1. ^ Blanchet PJ, Kivenko V (2016-09-23). "Drug-induced parkinsonism: diagnosis and management". Journal of Parkinsonism and Restless Legs Syndrome: 83–91. doi:10.2147/JPRLS.S99197.